Seattle Genetics cancer drug price may top $100,000

By Alina Selyukh

WASHINGTON | Mon Aug 22, 2011 7:33pm BST

WASHINGTON (Reuters) - The price of Seattle Genetics Inc's blood cancer drug Adcetris could top $100,000 for a course of treatment, becoming the latest cancer medicine to come at a high cost.

The U.S. Food and Drug Administration on Friday gave its nod to Adcetris, the first drug specifically indicated for anaplastic large cell lymphoma (ALCL) and the first one approved for Hodgkin's lymphoma since 1977.

Seattle Genetics on Monday said the drug will cost $4,500 per vial. In its clinical trials, the company said, patients on average received three vials per dose and between seven and nine doses per treatment.



http://uk.reuters.com/article/2011/08/22/us-seattlegenetics-idUKTRE77L5EB20110822

---